1101:
time in remission of 5.5 months (range: 0.4–30 months). In combination with decitabine, 7 participants achieved a CR (54%, 95% CI: 25, 81) with a median observed time in remission of 4.7 months (range: 1.0–18 months). The observed time in remission is the time from start of CR to data cut-off date or relapse from CR. In a phase 3 study of azacitidine and venetoclax in untreated acute myeloid leukemia not eligible for standard induction chemotherapy, the addition of venetoclax to azacitidine resulted in an improvement in median overall survival (14.7 months versus 9.6 months) and improved complete remission rates.
672:
649:
1078:
5-week ramp-up venetoclax schedule and then received venetoclax 400 mg once daily for 24 months measured from the rituximab start date. Rituximab was initiated after venetoclax ramp-up and given for 6 cycles (375 mg/m2 intravenously on cycle 1 day 1 and 500 mg/m2 intravenously on day 1 of cycles 2–6, with a 28-day cycle length). The comparator arm received 6 cycles of B+R (bendamustine 70 mg/m2 on days 1 and 2 of each 28-day cycle and rituximab at the above described dose and schedule).
1120:
Median PFS was not reached in either arm after a median follow-up duration of 28 months. The overall response rate was 85% in VEN+G arm compared to 71% in GClb arm, p=0.0007. The trial also demonstrated statistically significant improvements in rates of minimal residual disease negativity (less than one CLL cell per 10 leukocytes) in bone marrow and peripheral blood. Overall survival data were not mature at this analysis.
925:
received anti-AML treatment than in 2016-2018 (87.2% vs. 55.6%, respectively), and different outcomes were significanly improved in 2019-2021 comparing 2016-2018, for example: complete remission (44.7% vs. 19.4%, respectively), 30 day mortality rate (12.8% vs. 38.9%), 1-year overall survival (29.8% vs. 11.1%), 1-year relapse free survival (57.1% vs. 14.3%) and 1-year event free survival (25.5% vs. 2.8%).
31:
40:
5475:
1916:
1859:
1808:
1765:
1725:
1516:
2067:
850:
Venetoclax attaches to a protein called Bcl-2. This protein is present in high amounts in CLL cancer cells, where it helps the cells survive for longer in the body and makes them resistant to cancer medicines. By attaching to Bcl-2 and blocking its actions, venetoclax causes the death of cancer cells
1096:
Accelerated approval was based on two open-label non-randomized trials in participants with newly diagnosed AML who were >= 75 years of age or had comorbidities that precluded the use of intensive induction chemotherapy. Efficacy was established based on the rate of complete remission (CR) and CR
789:
InChI=1S/C45H50ClN7O7S/c1-45(2)15-11-33(39(26-45)31-3-5-34(46)6-4-31)29-51-17-19-52(20-18-51)35-7-9-38(42(24-35)60-36-23-32-12-16-47-43(32)49-28-36)44(54)50-61(57,58)37-8-10-40(41(25-37)53(55)56)48-27-30-13-21-59-22-14-30/h3-10,12,16,23-25,28,30,48H,11,13-15,17-22,26-27,29H2,1-2H3,(H,47,49)(H,50,54)
1193:
announced the results of a Phase III trial that showed a 34 percent reduction in the risk of death in AML patients who were ineligible for intensive chemotherapy treated with venetoclax plus azacitidine compared to azacitidine plus placebo. Several trials have assessed the combination of venetoclax
1100:
Study M14-358 (NCT02203773) was a non-randomized, open-label clinical trial of venetoclax in combination with azacitidine (n=67) or decitabine (n=13) in newly diagnosed participants with AML. In combination with azacitidine, 25 participants achieved a CR (37%, 95% CI: 26, 50) with a median observed
887:
In the EU, venetoclax monotherapy is indicated for the treatment of chronic lymphocytic leukemia (CLL) in the presence of 17p deletion or TP53 mutation in adults who are unsuitable for or have failed a B cell receptor pathway inhibitor and for the treatment of CLL in the absence of 17p deletion or
1104:
Study M14-387 (NCT02287233) was a non-randomized, open-label trial of venetoclax in combination with low-dose cytarabine (n=61) in newly diagnosed participants with AML, including participants with previous exposure to a hypomethylating agent for an antecedent hematologic disorder. In combination
1092:
In
November 2018, in the United States, venetoclax was approved in combination with azacitidine or decitabine or low-dose cytarabine for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults who are age 75 years or older, or who have comorbidities that preclude use of intensive
1119:
The major efficacy outcome was progression-free survival (PFS) assessed by an independent review committee. The trial demonstrated a statistically significant improvement in PFS for participants who received VEN+G compared with those who received GClb (HR 0.33; 95% CI: 0.22, 0.51; p<0.0001).
1077:
Approval was based on MURANO (NCT02005471), a randomized (1:1), multicenter, open-label trial of venetoclax with rituximab (VEN+R) versus bendamustine with rituximab (B+R) in 389 participants with CLL who had received at least one prior line of therapy. Participants in the VEN+R arm completed a
924:
A retrospective study examined the characteristics and outcomes of 83 AML patients, aged ≥75 years old, by comparing two periods: 2016-2018 (36 patients , before
Venetoclax approval) and 2019-2021 (47 patients, following Venetoclax approval): It was found that during 2019-2021 more ≥75 patients
1115:
Approval was based on CLL14 (NCT02242942), a randomized (1:1), multicenter, open label, actively controlled trial of venetoclax in combination with obinutuzumab (VEN+G) versus obinutuzumab in combination with chlorambucil (GClb) in 432 participants with previously untreated CLL with coexisting
978:
The maximum plasma concentration achieved after oral administration occurred 5–8 hours after dose. Steady state maximum concentration with low-fat meal conditions at the 400 mg once daily dose was found to be 2.1 ± 1.1 μg/mL. It is recommended that venetoclax be administered with a meal.
1048:
The efficacy of venetoclax was tested in a single-arm clinical trial of 106 participants with CLL who have a 17p deletion and who had received at least one prior therapy. Trial participants took venetoclax orally every day, beginning with 20 mg and increasing over a five-week period to
747:
2228:
2075:
1139:
manufactures
Venclexta. It is marketed by both Abbvie and Genentech USA, which is a member of the Roche Group. AbbVie and Genentech are both commercializing the drug within the United States, but only AbbVie has rights to do so outside of the U.S.
994:
as proven by in-vitro studies. Those using the drug should not consume grapefruit products because they contain CYP3A inhibitors. Additionally, while using venetoclax it is not recommended to use other drugs which contain CYP3A inhibitors (i.e.:
2004:
1123:
The FDA used the Real-Time
Oncology Review and Assessment Aid Pilot Program for this application and granted priority review as well as orphan drug and breakthrough therapy designations. Approval was granted 3.7 months ahead of the
982:
The apparent volume of distribution for venetoclax is approximately 256–321 L. It is highly bound to human plasma protein. Within a concentration range of 1-30 μM (0.87-26 μg/mL), the fraction unbound in plasma was less than 0.01.
1049:
400 mg. Results showed that 80 percent of trial participants experienced a complete or partial remission of their cancer. The trial was conducted in the US, Canada, France, Germany, Poland, the United
Kingdom, and Australia.
1045:(deletion located on the chromosome 17 short arm) and who have been treated with at least one prior therapy. Based on overall response rate, the indication was approved under accelerated FDA approval.
2229:"Venclexta/Venclyxto (venetoclax) Plus Azacitidine Demonstrates Statistically Significant Overall Survival Benefit and Improved Remission Rates in Treatment-Naïve Acute Myeloid Leukemia Patients"
2017:
1074:
In June 2018, the FDA granted regular approval to venetoclax for people with CLL or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy.
281:
1836:
1702:
2042:
1318:
4054:
1266:
3910:
2172:
1535:"P560: Improvement in overall and relapse free survival of AML patients over the age of 75 since the approval of venetoclax in a real-world single center study"
236:
1105:
with low-dose cytarabine, 13 participants achieved a CR (21%, 95% CI: 12, 34) with a median observed time in remission of 6 months (range: 0.03–25 months).
1292:
1580:"Targeting BCL2 With BH3 Mimetics: Basic Science and Clinical Application of Venetoclax in Chronic Lymphocytic Leukemia and Related B Cell Malignancies"
2322:
4047:
1462:
Text was copied from this source which is copyright
European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
5525:
4488:
4473:
134:
3970:
3022:
761:
1974:
4040:
2851:
2831:
2816:
1493:
1035:
designation to venetoclax for people with CLL or SLL who have relapsed, become intolerant to, or refractory to previous treatment.
5046:
4689:
2202:
1401:
3238:
1742:
5520:
3998:
2315:
970:
of CLL cells. Overexpression of Bcl-2 in some lymphoid malignancies has been linked to increased resistance to chemotherapy.
4182:
3605:
2180:
1785:
5495:
5160:
2757:
2713:
2591:
2123:"Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases - Patent US9174982 - PubChem"
2122:
2300:
185:
5510:
2516:
781:
102:
4580:
4106:
4015:
2308:
1242:
3032:
1659:
1627:
1186:
410:
266:
166:
3651:
2653:
2543:
1125:
917:
for newly diagnosed adults who are age 75 years or older, or those with other health problems where intensive
5500:
3573:
3556:
3431:
3195:
2573:
2173:"BRIEF-Roche Reports Positive Phase 3 Results For Venclexta/Venclyxto Combination In Acute Myeloid Leukaemia"
1175:
2043:"Ibrutinib and Idelalisib Continue to Impress in CLL, May Eventually Replace Chemotherapy for Some Patients"
1703:"FDA approves new drug for chronic lymphocytic leukemia in patients with a specific chromosomal abnormality"
4926:
3305:
2901:
1899:
1893:
1842:
1791:
1748:
1708:
1665:
1636:
1499:
1028:
865:
821:
667:
520:
1628:"Center for Drug Evaluation and Research - Application 208573Orig1s000 - Division Director Summary Review"
769:
CC1(CCC(=C(C1)c2ccc(cc2)Cl)CN3CCN(CC3)c4ccc(c(c4)Oc5cc6ccc6nc5)C(=O)NS(=O)(=O)c7ccc(c(c7)(=O))NCC8CCOCC8)C
589:
5107:
4083:
3507:
888:
TP53 mutation in adults who have failed both chemoimmunotherapy and a B cell receptor pathway inhibitor.
628:
4032:
2897:
2867:
937:(low white blood cell count), nausea, anemia, diarrhea, upper respiratory tract infection, fatigue, and
5535:
5465:
5232:
5081:
4830:
4332:
2687:
869:
825:
2792:
5550:
5540:
4557:
4423:
4136:
3873:
3753:
3743:
1447:
2147:
644:
4567:
4093:
3925:
3858:
3828:
3446:
2696:
4063:
4003:
3728:
3443:
2929:
2777:
2704:
222:
116:
4935:
4418:
4147:
3808:
3798:
3531:
3373:
1837:"FDA approves venetoclax for CLL or SLL, with or without 17p deletion, after one prior therapy"
1147:
billion. Competition as well as potential for combination is expected from other drugs such as
902:
829:
610:
569:
348:
1442:
509:
5545:
5530:
5515:
4493:
4433:
4403:
4306:
4142:
3080:
2727:
1933:
DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. (August 2020).
1039:
444:
4348:
4243:
4080:
3478:
3355:
2876:
1167:
1109:
1086:
1061:
1057:
1032:
942:
529:
379:
671:
648:
8:
5505:
5201:
4468:
4458:
4278:
3763:
3663:
3642:
3363:
3185:
3017:
2748:
2644:
1179:
1042:
835:
The most common side effects are low levels of neutrophils (a type of white blood cell),
435:
229:
2281:
2254:
1555:
1534:
4856:
4393:
2821:
2330:
1604:
1579:
1546:
1166:
As of 2016, venetoclax had been tested to treat other hematological cancers, including
945:
and severe neutropenia. Additionally, this drug may cause fertility problems in males.
196:
4533:
3945:
3519:
2353:
2286:
1956:
1609:
1560:
1346:
1190:
1143:
According to
Reuters 2016 Drugs to Watch, the 2020 forecast sales for venetoclax are
963:
600:
469:
318:
305:
293:
158:
1237:
1112:
to include all adults with CLL/SLL disregarding prior treatment or mutation status.
4373:
4215:
4210:
3950:
3707:
3422:
3056:
3041:
2762:
2276:
2266:
1946:
1599:
1591:
1550:
1542:
1171:
938:
684:
340:
249:
57:
1267:"Prescription medicines: registration of new chemical entities in Australia, 2017"
1211:
144:
5479:
3389:
3351:
3142:
2564:
2479:
2012:
1347:"Venclyxto 10 mg film-coated tablets - Summary of Product Characteristics (SmPC)"
1082:
1053:
358:
5310:
5208:
5156:
4754:
4067:
4009:
3543:
3134:
2628:
2492:
2379:
2349:
2336:
1038:
In April 2016, the FDA approved venetoclax for use in those with CLL who have
5489:
5367:
5257:
5219:
5196:
5128:
5123:
5113:
4889:
4885:
4873:
4680:
4463:
4428:
4248:
4228:
3883:
3843:
3213:
3086:
2967:
2910:
2668:
2617:
2253:
Molica M, Perrone S, Federico V, Alati C, Molica S, Rossi M (December 2023).
1920:
1863:
1812:
1769:
1729:
1520:
1323:
1000:
881:
873:
660:
2271:
5407:
5392:
5362:
5342:
5224:
5172:
5133:
5021:
5000:
4907:
4869:
4770:
4745:
4741:
4625:
4590:
4543:
4528:
4483:
4358:
4328:
4253:
4071:
3930:
3894:
3778:
3768:
3722:
3718:
3680:
3588:
3378:
3317:
3313:
3294:
3289:
3268:
3257:
3071:
3065:
3051:
3046:
2977:
2972:
2925:
2811:
2678:
2658:
2587:
2536:
2526:
2340:
2332:
2290:
1960:
1935:"Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia"
1613:
1564:
996:
959:
918:
244:
22:
1951:
1934:
5437:
5417:
5412:
5402:
5382:
5357:
5352:
5335:
5283:
5273:
5268:
5263:
5165:
5092:
5062:
5057:
5052:
5036:
5026:
5006:
4881:
4877:
4865:
4861:
4790:
4694:
4640:
4635:
4600:
4538:
4523:
4513:
4508:
4503:
4498:
4478:
4443:
4398:
4378:
4368:
4323:
4288:
4268:
4224:
4187:
4175:
4170:
4132:
4116:
4062:
3975:
3955:
3940:
3935:
3920:
3878:
3848:
3788:
3758:
3702:
3675:
3548:
3489:
3461:
3451:
3404:
3368:
3284:
3246:
3228:
3223:
3203:
3180:
3151:
3129:
3109:
3099:
2950:
2935:
2915:
2801:
2732:
2718:
2673:
2606:
2601:
2578:
2553:
2521:
2464:
2427:
2404:
2389:
2384:
2369:
1136:
1081:
The application for venetoclax in combination with rituximab was granted
1065:
1012:
1008:
934:
906:
152:
1071:
Venetoclax was approved for use in the
European Union in December 2016.
489:
5447:
5422:
5387:
5372:
5347:
5330:
5320:
5278:
5249:
5214:
5180:
5097:
5087:
5067:
5031:
5016:
5011:
4981:
4915:
4911:
4893:
4841:
4820:
4780:
4775:
4714:
4645:
4620:
4595:
4518:
4453:
4413:
4408:
4388:
4383:
4363:
4353:
4343:
4258:
4238:
4220:
4128:
3868:
3863:
3838:
3833:
3823:
3818:
3813:
3783:
3773:
3738:
3733:
3713:
3668:
3656:
3631:
3626:
3616:
3598:
3593:
3583:
3578:
3536:
3524:
3512:
3484:
3471:
3466:
3436:
3399:
3394:
3332:
3327:
3273:
3218:
3170:
3156:
3104:
3091:
3060:
2993:
2982:
2955:
2945:
2940:
2886:
2841:
2836:
2737:
2701:
2633:
2623:
2612:
2596:
2548:
2531:
2507:
2459:
2447:
2399:
2097:
1152:
914:
910:
817:
723:
500:
2255:"Venetoclax: A Game Changer in the Treatment of Younger AML Patients?"
2203:"EHA: AbbVie, Roche cement Venclexta's place in AML with survival win"
847:(low red blood cell counts), nose and throat infection and tiredness.
5442:
5432:
5427:
5397:
5377:
5325:
5315:
5303:
5298:
5244:
5239:
5185:
5118:
4991:
4986:
4971:
4966:
4961:
4951:
4946:
4941:
4846:
4836:
4815:
4810:
4805:
4800:
4795:
4785:
4765:
4729:
4724:
4719:
4709:
4704:
4671:
4666:
4661:
4630:
4610:
4605:
4448:
4438:
4263:
4111:
3980:
3960:
3915:
3905:
3899:
3803:
3748:
3697:
3621:
3611:
3566:
3553:
3494:
3456:
3384:
3322:
3263:
3252:
3208:
3165:
3124:
3118:
3114:
3076:
3003:
2998:
2988:
2960:
2920:
2881:
2856:
2846:
2806:
2452:
2442:
2437:
2432:
2394:
1402:"Venclexta- venetoclax kit Venclexta- venetoclax tablet, film coated"
1148:
1016:
1004:
967:
455:
392:
138:
1595:
5192:
4956:
4760:
4699:
4655:
4615:
4585:
4338:
4202:
4198:
4123:
3889:
3853:
3793:
3561:
3499:
3279:
3175:
3147:
2826:
2663:
836:
549:
480:
180:
901:
Venetoclax is also indicated as part of a combination therapy for
746:
616:
4296:
2782:
2683:
2497:
2358:
1975:"Inside the development of Venclexta, AbbVie's new leukemia drug"
1919:
This article incorporates text from this source, which is in the
1862:
This article incorporates text from this source, which is in the
1811:
This article incorporates text from this source, which is in the
1768:
This article incorporates text from this source, which is in the
1728:
This article incorporates text from this source, which is in the
1519:
This article incorporates text from this source, which is in the
1293:"Prescription medicines and biologicals: TGA annual summary 2017"
2422:
991:
987:
844:
840:
580:
371:
367:
5176:
4902:
4736:
4685:
4165:
1019:). Venetoclax is excreted from the body via the fecal route.
737:
560:
363:
39:
30:
1932:
872:(SLL). Indication does not depend on mutation status (e. g.
633:
5291:
5077:
4575:
4301:
4283:
4273:
4233:
4101:
877:
540:
78:
72:
63:
2252:
1894:"FDA approves venetoclax in combination for AML in adults"
1155:, both of which were also approved in 2014 to treat CLL.
87:
1319:"Health Canada New Drug Authorizations: 2016 Highlights"
2148:"Venetoclax | US Patents | Expiry | Expiration | Dates"
1396:
1394:
1392:
1390:
1388:
5463:
1386:
1384:
1382:
1380:
1378:
1376:
1374:
1372:
1370:
1368:
1194:
with intensive chemotherapy in younger AML patients.
103:
93:
90:
81:
69:
84:
75:
60:
864:In the US, venetoclax is indicated for adults with
851:and thereby slows down progression of the disease.
66:
1888:
1886:
1884:
1882:
1880:
1878:
1876:
1874:
1872:
1831:
1829:
1827:
1825:
1823:
1821:
1697:
1695:
1693:
1691:
1689:
1687:
1685:
1488:
1365:
1204:
1486:
1484:
1482:
1480:
1478:
1476:
1474:
1472:
1470:
1468:
941:(low platelet count). Major side effects include
5487:
1437:
1435:
1433:
1431:
1429:
1427:
1425:
1423:
468:
397:Feces (>99.9%; 20.8% as unchanged venetoclax)
1869:
1818:
1780:
1778:
1682:
962:-mimetic. Venetoclax blocks the anti-apoptotic
443:
1999:
1997:
1995:
1465:
4048:
2316:
2005:"Drugs to Watch 2016 - Market Insight Report"
1420:
1212:"Venetoclax (Venclexta) Use During Pregnancy"
1775:
1652:
1577:
1533:Moshe Y, Levi S, et al. (August 2023).
184:
1992:
1052:The application for venetoclax was granted
332:In general: ℞ (Prescription only)
4055:
4041:
2323:
2309:
933:Common side effects of venetoclax include
891:
670:
647:
508:
2280:
2270:
1950:
1603:
1554:
1532:
1494:"FDA approves venetoclax for CLL and SLL"
896:
528:
905:(AML). For this purpose it is used with
1108:In May 2019, the label was extended by
643:
488:
157:
5488:
1584:Clinical Pharmacology and Therapeutics
1297:Therapeutic Goods Administration (TGA)
1271:Therapeutic Goods Administration (TGA)
1158:Venetoclax is patented by AbbVie Inc.
1131:
953:
661:
324:
299:
4036:
2304:
1187:European Hematology Association (EHA)
609:
588:
568:
312:
175:
143:
5526:Drugs developed by Hoffmann-La Roche
1578:Roberts AW, Huang D (January 2017).
615:
248:
2592:ribonucleotide reductase inhibitors
1939:The New England Journal of Medicine
973:
548:
459:
13:
2758:Ribonucleotide reductase inhibitor
2714:Ribonucleotide reductase inhibitor
1547:10.1097/01.HS9.0000969144.75498.e6
422:-({3-nitro-4-phenyl}sulfonyl)-2-(1
14:
5562:
2517:Dihydrofolate reductase inhibitor
1786:"Drug Trials Snapshot: Venclexta"
426:-pyrrolopyridin-5-yloxy)benzamide
275:
207:
5473:
1914:
1857:
1806:
1763:
1743:"Venetoclax (Venclexta) Tablets"
1723:
1514:
1243:Therapeutic Goods Administration
704:
701:
695:
56:
38:
29:
2246:
2221:
2195:
2165:
2140:
2115:
2090:
2068:"United States Patent: 9174982"
2060:
2035:
2016:. February 2016. Archived from
1967:
1926:
1735:
1620:
1571:
1526:
948:
928:
854:
795:Key:LQBVNQSMGBZMKD-UHFFFAOYSA-N
2654:Thymidylate synthase inhibitor
2544:Thymidylate synthase inhibitor
2179:. 13 June 2020. Archived from
1713:(Press release). 11 April 2016
1339:
1311:
1285:
1259:
1230:
1126:Prescription Drug User Fee Act
716:
710:
689:
288:
1:
2574:Adenosine deaminase inhibitor
2415:Block microtubule disassembly
1197:
1176:diffuse large B-cell lymphoma
986:Venetoclax is metabolized by
808:, sold under the brand names
418:4-(4-{methyl}-1-piperazinyl)-
5521:Drugs developed by Genentech
1900:Food and Drug Administration
1847:(Press release). 8 June 2018
1843:Food and Drug Administration
1792:Food and Drug Administration
1749:Food and Drug Administration
1709:Food and Drug Administration
1666:Food and Drug Administration
1637:Food and Drug Administration
1504:(Press release). 15 May 2019
1500:Food and Drug Administration
1189:annual congress, AbbVie and
1029:Food and Drug Administration
966:(Bcl-2) protein, leading to
866:chronic lymphocytic leukemia
822:chronic lymphocytic leukemia
7:
1161:
1027:In 2015, the United States
10:
5567:
4558:Tyrosine kinase inhibitors
1022:
870:small lymphocytic lymphoma
859:
826:small lymphocytic lymphoma
820:used to treat adults with
679:Chemical and physical data
129:GDC-0199, ABT-199, RG-7601
5496:Drugs developed by AbbVie
5148:
4925:
4566:
4556:
4424:Mirvetuximab soravtansine
4316:
4197:
4157:
4092:
4079:
3993:
3874:Omacetaxine mepesuccinate
3754:Ciltacabtagene autoleucel
3744:Brexucabtagene autoleucel
3690:
3641:
3421:
3414:
3350:
3304:
3237:
3194:
3031:
3016:
2896:
2866:
2791:
2776:
2747:
2643:
2563:
2506:
2489:
2478:
2414:
2367:
2348:
1448:European Medicines Agency
777:
757:
735:
722:
683:
678:
659:
627:
599:
579:
559:
539:
519:
499:
479:
454:
434:
406:
401:
391:
378:
357:
347:
339:
265:
260:
235:
221:
195:
165:
151:
133:
125:
115:
51:
46:
37:
28:
5511:4-Chlorophenyl compounds
4568:Receptor tyrosine kinase
4094:Receptor tyrosine kinase
3926:Talimogene laherparepvec
3859:Nadofaragene firadenovec
3829:Lisocabtagene maraleucel
2778:Topoisomerase inhibitors
2697:DNA polymerase inhibitor
2127:pubchem.ncbi.nlm.nih.gov
1093:induction chemotherapy.
4158:Others for solid tumors
4064:Targeted cancer therapy
3729:Axicabtagene ciloleucel
2333:chemotherapeutic agents
2272:10.3390/cancers16010073
1185:On 13 June 2020 at the
892:Other types of leukemia
4419:Loncastuximab tesirine
4148:Trastuzumab deruxtecan
3911:Sitimagene ceradenovec
3809:Idecabtagene vicleucel
3374:Methyl aminolevulinate
1168:non-Hodgkin's lymphoma
903:acute myeloid leukemia
897:Acute myeloid leukemia
830:acute myeloid leukemia
4494:Sacituzumab govitecan
4434:Moxetumomab pasudotox
4404:Inotuzumab ozogamicin
4307:Gemtuzumab ozogamicin
4143:Trastuzumab emtansine
4084:monoclonal antibodies
4068:antineoplastic agents
3385:Porphyrin derivatives
3081:Melphalan flufenamide
2728:Hypomethylating agent
2337:antineoplastic agents
1952:10.1056/NEJMoa2012971
968:programmed cell death
5501:Antineoplastic drugs
4349:Belantamab mafodotin
3714:Asparagine depleters
3643:Receptor antagonists
3557:+abiraterone acetate
1541:. 7(S3) (1): 89–98.
1238:"AusPAR: Venetoclax"
1116:medical conditions.
1110:accelerated approval
1087:breakthrough therapy
1062:breakthrough therapy
1058:accelerated approval
1033:breakthrough therapy
943:tumor lysis syndrome
121:Venclexta, Venclyxto
5202:Denileukin diftitox
4864:(ALK, ROS1, NTRK),
4469:Polatuzumab vedotin
4459:Oportuzumab monatox
3764:Denileukin diftitox
3664:Retinoid X receptor
3364:Aminolevulinic acid
3186:Triethylenemelamine
3018:Crosslinking of DNA
2749:Deoxyribonucleotide
2688:+gimeracil/oteracil
1660:"Venclexta Tablets"
1180:follicular lymphoma
1132:Society and culture
954:Mechanism of action
308:(Prescription only)
284:(Prescription only)
25:
4888:(ROS1, TRK, ALK),
4394:Enfortumab vedotin
4020:Never to phase III
2822:Etirinotecan pegol
2078:on 11 October 2018
1904:. 21 November 2018
1452:. 21 December 2016
1408:. 12 November 2019
1031:(FDA) granted the
21:
5536:Phenylpiperazines
5461:
5460:
5144:
5143:
4552:
4551:
4534:Tisotumab vedotin
4030:
4029:
3989:
3988:
3946:Tigilanol tiglate
3423:Enzyme inhibitors
3346:
3345:
3342:
3341:
3042:Nitrogen mustards
3012:
3011:
2772:
2771:
2474:
2473:
2152:PharmaCompass.com
964:B-cell lymphoma-2
803:
802:
748:Interactive image
629:CompTox Dashboard
328:
316:
303:
291:
279:
211:
178:
5558:
5551:Tetrahydropyrans
5541:Pyrrolopyridines
5478:
5477:
5476:
5469:
5175:peptide against
4748:(AXL, ALK, LTK))
4564:
4563:
4374:Dinutuximab beta
4090:
4089:
4057:
4050:
4043:
4034:
4033:
3951:Tisagenlecleucel
3708:Arsenic trioxide
3419:
3418:
3352:Photosensitizers
3143:Alkyl sulfonates
3057:Cyclophosphamide
3029:
3028:
2968:Anthracenediones
2789:
2788:
2763:Hydroxycarbamide
2504:
2503:
2487:
2486:
2365:
2364:
2325:
2318:
2311:
2302:
2301:
2295:
2294:
2284:
2274:
2250:
2244:
2243:
2241:
2239:
2225:
2219:
2218:
2216:
2214:
2199:
2193:
2192:
2190:
2188:
2169:
2163:
2162:
2160:
2158:
2144:
2138:
2137:
2135:
2133:
2119:
2113:
2112:
2110:
2108:
2094:
2088:
2087:
2085:
2083:
2074:. Archived from
2064:
2058:
2057:
2055:
2053:
2039:
2033:
2032:
2030:
2028:
2022:
2009:
2001:
1990:
1989:
1987:
1985:
1971:
1965:
1964:
1954:
1930:
1924:
1918:
1917:
1913:
1911:
1909:
1890:
1867:
1861:
1860:
1856:
1854:
1852:
1833:
1816:
1810:
1809:
1805:
1803:
1801:
1782:
1773:
1767:
1766:
1762:
1760:
1758:
1739:
1733:
1727:
1726:
1722:
1720:
1718:
1699:
1680:
1679:
1677:
1675:
1656:
1650:
1649:
1647:
1645:
1632:
1624:
1618:
1617:
1607:
1575:
1569:
1568:
1558:
1530:
1524:
1518:
1517:
1513:
1511:
1509:
1490:
1463:
1461:
1459:
1457:
1443:"Venclyxto EPAR"
1439:
1418:
1417:
1415:
1413:
1398:
1363:
1362:
1360:
1358:
1343:
1337:
1336:
1334:
1332:
1315:
1309:
1308:
1306:
1304:
1289:
1283:
1282:
1280:
1278:
1263:
1257:
1256:
1254:
1252:
1234:
1228:
1227:
1225:
1223:
1208:
1172:multiple myeloma
1146:
1064:designation and
974:Pharmacokinetics
958:Venetoclax is a
939:thrombocytopenia
921:cannot be used.
750:
730:
718:
712:
706:
703:
697:
691:
674:
663:
652:
651:
637:
635:
619:
613:
592:
572:
552:
532:
512:
492:
472:
462:
461:
447:
383:
326:
323:
314:
311:
301:
298:
290:
287:
277:
274:
252:
209:
206:
188:
177:
174:
161:
147:
107:
100:
99:
96:
95:
92:
89:
86:
83:
80:
77:
74:
71:
68:
65:
62:
42:
33:
26:
24:
20:
5566:
5565:
5561:
5560:
5559:
5557:
5556:
5555:
5486:
5485:
5484:
5474:
5472:
5464:
5462:
5457:
5311:Pi3K inhibitors
5209:mTOR inhibitors
5140:
4921:
4892:(VEGFR, FGFR),
4548:
4312:
4193:
4153:
4075:
4061:
4031:
4026:
4025:
4010:Clinical trials
3985:
3691:Other/ungrouped
3686:
3637:
3410:
3390:Porfimer sodium
3338:
3300:
3233:
3190:
3020:
3008:
2892:
2862:
2780:
2768:
2743:
2639:
2559:
2495:
2493:antimetabolites
2491:
2490:DNA precursors/
2482:
2480:DNA replication
2470:
2410:
2380:Vinca alkaloids
2356:
2344:
2329:
2299:
2298:
2251:
2247:
2237:
2235:
2227:
2226:
2222:
2212:
2210:
2201:
2200:
2196:
2186:
2184:
2183:on 15 June 2020
2171:
2170:
2166:
2156:
2154:
2146:
2145:
2141:
2131:
2129:
2121:
2120:
2116:
2106:
2104:
2102:drugcentral.org
2096:
2095:
2091:
2081:
2079:
2072:patft.uspto.gov
2066:
2065:
2061:
2051:
2049:
2041:
2040:
2036:
2026:
2024:
2020:
2013:Thomson Reuters
2007:
2003:
2002:
1993:
1983:
1981:
1973:
1972:
1968:
1931:
1927:
1915:
1907:
1905:
1892:
1891:
1870:
1858:
1850:
1848:
1835:
1834:
1819:
1807:
1799:
1797:
1796:. 11 April 2016
1784:
1783:
1776:
1764:
1756:
1754:
1753:. 11 April 2016
1741:
1740:
1736:
1724:
1716:
1714:
1701:
1700:
1683:
1673:
1671:
1658:
1657:
1653:
1643:
1641:
1630:
1626:
1625:
1621:
1596:10.1002/cpt.553
1576:
1572:
1531:
1527:
1515:
1507:
1505:
1492:
1491:
1466:
1455:
1453:
1441:
1440:
1421:
1411:
1409:
1400:
1399:
1366:
1356:
1354:
1353:. 21 April 2020
1345:
1344:
1340:
1330:
1328:
1327:. 14 March 2017
1317:
1316:
1312:
1302:
1300:
1291:
1290:
1286:
1276:
1274:
1265:
1264:
1260:
1250:
1248:
1247:. 26 April 2022
1236:
1235:
1231:
1221:
1219:
1210:
1209:
1205:
1200:
1164:
1144:
1134:
1083:priority review
1054:priority review
1025:
976:
956:
951:
931:
899:
894:
862:
857:
799:
796:
791:
785:
784:
773:
770:
765:
764:
753:
728:
715:
709:
700:
694:
655:
631:
623:
595:
575:
555:
535:
515:
495:
475:
458:
450:
430:
427:
414:
413:
381:
349:Protein binding
341:Pharmacokinetic
335:
256:
224:
217:
198:
191:
105:
101:
59:
55:
17:
12:
11:
5:
5564:
5554:
5553:
5548:
5543:
5538:
5533:
5528:
5523:
5518:
5513:
5508:
5503:
5498:
5483:
5482:
5459:
5458:
5456:
5455:
5450:
5445:
5440:
5435:
5430:
5425:
5420:
5415:
5410:
5405:
5400:
5395:
5390:
5385:
5380:
5375:
5370:
5365:
5360:
5355:
5350:
5345:
5340:
5339:
5338:
5333:
5328:
5323:
5318:
5308:
5307:
5306:
5301:
5288:
5287:
5286:
5281:
5276:
5271:
5266:
5258:CDK inhibitors
5254:
5253:
5252:
5247:
5242:
5229:
5228:
5227:
5222:
5217:
5205:
5189:
5169:
5157:fusion protein
5152:
5150:
5146:
5145:
5142:
5141:
5139:
5138:
5137:
5136:
5131:
5126:
5121:
5116:
5103:
5102:
5101:
5100:
5095:
5090:
5073:
5072:
5071:
5070:
5065:
5060:
5055:
5042:
5041:
5040:
5039:
5034:
5029:
5024:
5019:
5014:
5009:
4996:
4995:
4989:
4977:
4976:
4975:
4974:
4969:
4964:
4959:
4954:
4949:
4944:
4931:
4929:
4923:
4922:
4920:
4919:
4898:
4897:
4896:(VEGFR, EGFR).
4852:
4851:
4850:
4849:
4844:
4839:
4826:
4825:
4824:
4823:
4818:
4813:
4808:
4803:
4798:
4793:
4788:
4783:
4778:
4773:
4768:
4763:
4750:
4749:
4733:
4727:
4722:
4717:
4712:
4707:
4702:
4697:
4677:
4676:
4675:
4674:
4669:
4664:
4654:HER1/EGFR and
4650:
4649:
4643:
4638:
4633:
4628:
4623:
4618:
4613:
4608:
4603:
4598:
4593:
4588:
4572:
4570:
4561:
4554:
4553:
4550:
4549:
4547:
4546:
4541:
4536:
4531:
4526:
4521:
4516:
4511:
4506:
4501:
4496:
4491:
4486:
4481:
4476:
4471:
4466:
4461:
4456:
4451:
4446:
4441:
4436:
4431:
4426:
4421:
4416:
4411:
4406:
4401:
4396:
4391:
4386:
4381:
4376:
4371:
4366:
4361:
4356:
4351:
4346:
4341:
4336:
4333:+hyaluronidase
4326:
4320:
4318:
4314:
4313:
4311:
4310:
4293:
4292:
4266:
4261:
4256:
4251:
4246:
4241:
4207:
4205:
4195:
4194:
4192:
4191:
4179:
4173:
4161:
4159:
4155:
4154:
4152:
4151:
4145:
4140:
4137:+hyaluronidase
4120:
4114:
4098:
4096:
4087:
4077:
4076:
4060:
4059:
4052:
4045:
4037:
4028:
4027:
4024:
4023:
4022:
4021:
4018:
4007:
4001:
3995:
3994:
3991:
3990:
3987:
3986:
3984:
3983:
3978:
3973:
3968:
3963:
3958:
3953:
3948:
3943:
3938:
3933:
3928:
3923:
3918:
3913:
3908:
3903:
3897:
3886:
3881:
3876:
3871:
3866:
3861:
3856:
3851:
3846:
3841:
3836:
3831:
3826:
3821:
3816:
3811:
3806:
3801:
3796:
3791:
3786:
3781:
3776:
3771:
3766:
3761:
3756:
3751:
3746:
3741:
3736:
3731:
3726:
3710:
3705:
3700:
3694:
3692:
3688:
3687:
3685:
3684:
3672:
3660:
3647:
3645:
3639:
3638:
3636:
3635:
3629:
3624:
3619:
3614:
3602:
3596:
3591:
3586:
3581:
3570:
3564:
3559:
3551:
3544:PARP inhibitor
3540:
3528:
3516:
3504:
3503:
3502:
3497:
3492:
3487:
3475:
3469:
3464:
3459:
3454:
3440:
3427:
3425:
3416:
3412:
3411:
3409:
3408:
3402:
3397:
3392:
3381:
3376:
3371:
3366:
3360:
3358:
3348:
3347:
3344:
3343:
3340:
3339:
3337:
3336:
3330:
3325:
3320:
3310:
3308:
3302:
3301:
3299:
3298:
3292:
3287:
3276:
3271:
3266:
3261:
3249:
3243:
3241:
3235:
3234:
3232:
3231:
3226:
3221:
3216:
3211:
3206:
3200:
3198:
3196:Platinum-based
3192:
3191:
3189:
3188:
3183:
3178:
3173:
3161:
3160:
3154:
3138:
3137:
3132:
3127:
3122:
3112:
3107:
3095:
3094:
3089:
3084:
3074:
3069:
3063:
3054:
3049:
3037:
3035:
3026:
3014:
3013:
3010:
3009:
3007:
3006:
3001:
2996:
2991:
2986:
2980:
2975:
2964:
2958:
2953:
2948:
2943:
2938:
2933:
2923:
2918:
2911:Anthracyclines
2906:
2904:
2894:
2893:
2891:
2890:
2884:
2872:
2870:
2864:
2863:
2861:
2860:
2854:
2849:
2844:
2839:
2834:
2829:
2824:
2819:
2814:
2809:
2797:
2795:
2786:
2774:
2773:
2770:
2769:
2767:
2766:
2753:
2751:
2745:
2744:
2742:
2741:
2735:
2723:
2722:
2709:
2708:
2692:
2691:
2681:
2676:
2671:
2666:
2661:
2649:
2647:
2641:
2640:
2638:
2637:
2631:
2629:Mercaptopurine
2620:
2615:
2610:
2604:
2599:
2583:
2582:
2569:
2567:
2561:
2560:
2558:
2557:
2551:
2540:
2534:
2529:
2524:
2512:
2510:
2501:
2484:
2476:
2475:
2472:
2471:
2469:
2468:
2456:
2450:
2445:
2440:
2435:
2430:
2418:
2416:
2412:
2411:
2409:
2408:
2402:
2397:
2392:
2387:
2375:
2373:
2362:
2346:
2345:
2331:Intracellular
2328:
2327:
2320:
2313:
2305:
2297:
2296:
2245:
2220:
2209:. 13 June 2020
2194:
2164:
2139:
2114:
2089:
2059:
2034:
2023:on 31 May 2021
1991:
1979:BioPharma Dive
1966:
1945:(7): 617–629.
1925:
1868:
1817:
1774:
1734:
1681:
1651:
1619:
1570:
1525:
1464:
1419:
1364:
1338:
1310:
1299:. 21 June 2022
1284:
1273:. 21 June 2022
1258:
1229:
1202:
1201:
1199:
1196:
1163:
1160:
1133:
1130:
1128:(PDUFA) date.
1024:
1021:
975:
972:
955:
952:
950:
947:
930:
927:
913:, or low-dose
898:
895:
893:
890:
861:
858:
856:
853:
801:
800:
798:
797:
794:
792:
788:
780:
779:
778:
775:
774:
772:
771:
768:
760:
759:
758:
755:
754:
752:
751:
743:
741:
733:
732:
726:
720:
719:
713:
707:
698:
692:
687:
681:
680:
676:
675:
665:
657:
656:
654:
653:
645:DTXSID30154863
640:
638:
625:
624:
622:
621:
605:
603:
597:
596:
594:
593:
585:
583:
577:
576:
574:
573:
565:
563:
557:
556:
554:
553:
545:
543:
537:
536:
534:
533:
525:
523:
517:
516:
514:
513:
505:
503:
497:
496:
494:
493:
485:
483:
477:
476:
474:
473:
465:
463:
452:
451:
449:
448:
440:
438:
432:
431:
429:
428:
417:
409:
408:
407:
404:
403:
399:
398:
395:
389:
388:
385:
376:
375:
361:
355:
354:
351:
345:
344:
337:
336:
334:
333:
330:
321:
309:
296:
285:
271:
269:
263:
262:
258:
257:
255:
254:
241:
239:
233:
232:
227:
225:administration
219:
218:
216:
215:
213:
203:
201:
193:
192:
190:
189:
171:
169:
163:
162:
155:
149:
148:
141:
131:
130:
127:
123:
122:
119:
113:
112:
53:
49:
48:
44:
43:
35:
34:
15:
9:
6:
4:
3:
2:
5563:
5552:
5549:
5547:
5544:
5542:
5539:
5537:
5534:
5532:
5529:
5527:
5524:
5522:
5519:
5517:
5514:
5512:
5509:
5507:
5504:
5502:
5499:
5497:
5494:
5493:
5491:
5481:
5471:
5470:
5467:
5454:
5451:
5449:
5446:
5444:
5441:
5439:
5436:
5434:
5431:
5429:
5426:
5424:
5421:
5419:
5416:
5414:
5411:
5409:
5406:
5404:
5401:
5399:
5396:
5394:
5391:
5389:
5386:
5384:
5381:
5379:
5376:
5374:
5371:
5369:
5368:Larotrectinib
5366:
5364:
5361:
5359:
5356:
5354:
5351:
5349:
5346:
5344:
5341:
5337:
5334:
5332:
5329:
5327:
5324:
5322:
5319:
5317:
5314:
5313:
5312:
5309:
5305:
5302:
5300:
5297:
5296:
5295:
5293:
5289:
5285:
5282:
5280:
5277:
5275:
5272:
5270:
5267:
5265:
5262:
5261:
5260:
5259:
5255:
5251:
5248:
5246:
5243:
5241:
5238:
5237:
5236:
5234:
5230:
5226:
5223:
5221:
5220:Ridaforolimus
5218:
5216:
5213:
5212:
5211:
5210:
5206:
5203:
5199:
5198:
5194:
5190:
5187:
5183:
5182:
5178:
5174:
5170:
5167:
5163:
5162:
5158:
5154:
5153:
5151:
5147:
5135:
5132:
5130:
5129:Pirtobrutinib
5127:
5125:
5124:Orelabrutinib
5122:
5120:
5117:
5115:
5114:Acalabrutinib
5112:
5111:
5110:
5109:
5105:
5104:
5099:
5096:
5094:
5091:
5089:
5086:
5085:
5084:
5083:
5079:
5075:
5074:
5069:
5066:
5064:
5061:
5059:
5056:
5054:
5051:
5050:
5049:
5048:
5044:
5043:
5038:
5035:
5033:
5030:
5028:
5025:
5023:
5020:
5018:
5015:
5013:
5010:
5008:
5005:
5004:
5003:
5002:
4998:
4997:
4993:
4990:
4988:
4984:
4983:
4979:
4978:
4973:
4970:
4968:
4965:
4963:
4960:
4958:
4955:
4953:
4950:
4948:
4945:
4943:
4940:
4939:
4938:
4937:
4933:
4932:
4930:
4928:
4924:
4917:
4913:
4909:
4906:
4904:
4900:
4899:
4895:
4891:
4890:Selpercatinib
4887:
4886:Repotrectinib
4883:
4879:
4875:
4874:Larotrectinib
4871:
4867:
4863:
4860:
4858:
4854:
4853:
4848:
4845:
4843:
4840:
4838:
4835:
4834:
4833:
4832:
4828:
4827:
4822:
4819:
4817:
4814:
4812:
4809:
4807:
4804:
4802:
4799:
4797:
4794:
4792:
4789:
4787:
4784:
4782:
4779:
4777:
4774:
4772:
4769:
4767:
4764:
4762:
4759:
4758:
4757:
4756:
4752:
4751:
4747:
4743:
4739:
4738:
4734:
4731:
4728:
4726:
4723:
4721:
4718:
4716:
4713:
4711:
4708:
4706:
4703:
4701:
4698:
4696:
4692:
4691:
4687:
4682:
4681:RTK class III
4679:
4678:
4673:
4670:
4668:
4665:
4663:
4660:
4659:
4658:
4657:
4652:
4651:
4647:
4644:
4642:
4639:
4637:
4634:
4632:
4629:
4627:
4624:
4622:
4619:
4617:
4614:
4612:
4609:
4607:
4604:
4602:
4599:
4597:
4594:
4592:
4589:
4587:
4583:
4582:
4577:
4574:
4573:
4571:
4569:
4565:
4562:
4559:
4555:
4545:
4542:
4540:
4537:
4535:
4532:
4530:
4527:
4525:
4522:
4520:
4517:
4515:
4512:
4510:
4507:
4505:
4502:
4500:
4497:
4495:
4492:
4490:
4487:
4485:
4482:
4480:
4477:
4475:
4472:
4470:
4467:
4465:
4464:Pembrolizumab
4462:
4460:
4457:
4455:
4452:
4450:
4447:
4445:
4442:
4440:
4437:
4435:
4432:
4430:
4429:Mogamulizumab
4427:
4425:
4422:
4420:
4417:
4415:
4412:
4410:
4407:
4405:
4402:
4400:
4397:
4395:
4392:
4390:
4387:
4385:
4382:
4380:
4377:
4375:
4372:
4370:
4367:
4365:
4362:
4360:
4357:
4355:
4352:
4350:
4347:
4345:
4342:
4340:
4337:
4334:
4330:
4327:
4325:
4322:
4321:
4319:
4315:
4308:
4304:
4303:
4298:
4295:
4294:
4290:
4286:
4285:
4280:
4276:
4275:
4270:
4267:
4265:
4262:
4260:
4257:
4255:
4252:
4250:
4249:Mosunetuzumab
4247:
4245:
4242:
4240:
4236:
4235:
4230:
4229:Mosunetuzumab
4226:
4222:
4218:
4217:
4212:
4209:
4208:
4206:
4204:
4200:
4196:
4189:
4185:
4184:
4180:
4177:
4174:
4172:
4168:
4167:
4163:
4162:
4160:
4156:
4149:
4146:
4144:
4141:
4138:
4134:
4130:
4126:
4125:
4121:
4118:
4115:
4113:
4109:
4108:
4103:
4100:
4099:
4097:
4095:
4091:
4088:
4085:
4082:
4078:
4073:
4069:
4065:
4058:
4053:
4051:
4046:
4044:
4039:
4038:
4035:
4019:
4017:
4014:
4013:
4011:
4008:
4005:
4002:
4000:
3997:
3996:
3992:
3982:
3979:
3977:
3974:
3972:
3969:
3967:
3964:
3962:
3959:
3957:
3954:
3952:
3949:
3947:
3944:
3942:
3939:
3937:
3934:
3932:
3929:
3927:
3924:
3922:
3919:
3917:
3914:
3912:
3909:
3907:
3904:
3901:
3898:
3896:
3892:
3891:
3887:
3885:
3884:Tabelecleucel
3882:
3880:
3877:
3875:
3872:
3870:
3867:
3865:
3862:
3860:
3857:
3855:
3852:
3850:
3847:
3845:
3844:Lurbinectedin
3842:
3840:
3837:
3835:
3832:
3830:
3827:
3825:
3822:
3820:
3817:
3815:
3812:
3810:
3807:
3805:
3802:
3800:
3797:
3795:
3792:
3790:
3787:
3785:
3782:
3780:
3777:
3775:
3772:
3770:
3767:
3765:
3762:
3760:
3757:
3755:
3752:
3750:
3747:
3745:
3742:
3740:
3737:
3735:
3732:
3730:
3727:
3724:
3720:
3716:
3715:
3711:
3709:
3706:
3704:
3701:
3699:
3696:
3695:
3693:
3689:
3682:
3678:
3677:
3673:
3670:
3666:
3665:
3661:
3658:
3654:
3653:
3649:
3648:
3646:
3644:
3640:
3633:
3630:
3628:
3625:
3623:
3620:
3618:
3615:
3613:
3609:
3607:
3603:
3600:
3597:
3595:
3592:
3590:
3587:
3585:
3582:
3580:
3576:
3575:
3571:
3568:
3565:
3563:
3560:
3558:
3555:
3552:
3550:
3546:
3545:
3541:
3538:
3534:
3533:
3529:
3526:
3522:
3521:
3517:
3514:
3510:
3509:
3505:
3501:
3498:
3496:
3493:
3491:
3488:
3486:
3483:
3482:
3481:
3480:
3476:
3473:
3470:
3468:
3465:
3463:
3460:
3458:
3455:
3453:
3449:
3448:
3445:
3441:
3438:
3434:
3433:
3429:
3428:
3426:
3424:
3420:
3417:
3413:
3406:
3403:
3401:
3398:
3396:
3393:
3391:
3387:
3386:
3382:
3380:
3377:
3375:
3372:
3370:
3367:
3365:
3362:
3361:
3359:
3357:
3353:
3349:
3334:
3331:
3329:
3326:
3324:
3321:
3319:
3315:
3312:
3311:
3309:
3307:
3306:Intercalation
3303:
3296:
3293:
3291:
3288:
3286:
3282:
3281:
3277:
3275:
3272:
3270:
3267:
3265:
3262:
3259:
3255:
3254:
3250:
3248:
3245:
3244:
3242:
3240:
3236:
3230:
3227:
3225:
3222:
3220:
3217:
3215:
3214:Dicycloplatin
3212:
3210:
3207:
3205:
3202:
3201:
3199:
3197:
3193:
3187:
3184:
3182:
3179:
3177:
3174:
3172:
3169:
3167:
3163:
3162:
3158:
3155:
3153:
3149:
3146:
3144:
3140:
3139:
3136:
3133:
3131:
3128:
3126:
3123:
3120:
3116:
3113:
3111:
3108:
3106:
3103:
3101:
3097:
3096:
3093:
3090:
3088:
3087:Prednimustine
3085:
3082:
3078:
3075:
3073:
3070:
3067:
3064:
3062:
3058:
3055:
3053:
3050:
3048:
3045:
3043:
3039:
3038:
3036:
3034:
3030:
3027:
3024:
3019:
3015:
3005:
3002:
3000:
2997:
2995:
2992:
2990:
2987:
2984:
2981:
2979:
2976:
2974:
2970:
2969:
2965:
2962:
2959:
2957:
2954:
2952:
2949:
2947:
2944:
2942:
2939:
2937:
2934:
2931:
2927:
2924:
2922:
2919:
2917:
2913:
2912:
2908:
2907:
2905:
2903:
2902:Intercalation
2899:
2895:
2888:
2885:
2883:
2879:
2878:
2874:
2873:
2871:
2869:
2865:
2858:
2855:
2853:
2850:
2848:
2845:
2843:
2840:
2838:
2835:
2833:
2830:
2828:
2825:
2823:
2820:
2818:
2815:
2813:
2810:
2808:
2804:
2803:
2799:
2798:
2796:
2794:
2790:
2787:
2784:
2779:
2775:
2764:
2760:
2759:
2755:
2754:
2752:
2750:
2746:
2739:
2736:
2734:
2730:
2729:
2725:
2724:
2720:
2716:
2715:
2711:
2710:
2706:
2705:+daunorubicin
2703:
2699:
2698:
2694:
2693:
2689:
2685:
2682:
2680:
2677:
2675:
2672:
2670:
2669:Doxifluridine
2667:
2665:
2662:
2660:
2656:
2655:
2651:
2650:
2648:
2646:
2642:
2635:
2632:
2630:
2626:
2625:
2621:
2619:
2618:Rabacfosadine
2616:
2614:
2611:
2608:
2605:
2603:
2600:
2598:
2594:
2593:
2589:
2585:
2584:
2580:
2576:
2575:
2571:
2570:
2568:
2566:
2562:
2555:
2552:
2550:
2546:
2545:
2541:
2538:
2535:
2533:
2530:
2528:
2525:
2523:
2519:
2518:
2514:
2513:
2511:
2509:
2505:
2502:
2499:
2494:
2488:
2485:
2481:
2477:
2466:
2462:
2461:
2457:
2454:
2451:
2449:
2446:
2444:
2441:
2439:
2436:
2434:
2431:
2429:
2425:
2424:
2420:
2419:
2417:
2413:
2406:
2403:
2401:
2398:
2396:
2393:
2391:
2388:
2386:
2382:
2381:
2377:
2376:
2374:
2371:
2366:
2363:
2360:
2355:
2351:
2347:
2342:
2338:
2334:
2326:
2321:
2319:
2314:
2312:
2307:
2306:
2303:
2292:
2288:
2283:
2278:
2273:
2268:
2264:
2260:
2256:
2249:
2234:
2230:
2224:
2208:
2204:
2198:
2182:
2178:
2174:
2168:
2153:
2149:
2143:
2128:
2124:
2118:
2103:
2099:
2093:
2077:
2073:
2069:
2063:
2048:
2044:
2038:
2019:
2015:
2014:
2006:
2000:
1998:
1996:
1980:
1976:
1970:
1962:
1958:
1953:
1948:
1944:
1940:
1936:
1929:
1922:
1921:public domain
1903:
1901:
1895:
1889:
1887:
1885:
1883:
1881:
1879:
1877:
1875:
1873:
1865:
1864:public domain
1846:
1844:
1838:
1832:
1830:
1828:
1826:
1824:
1822:
1814:
1813:public domain
1795:
1793:
1787:
1781:
1779:
1771:
1770:public domain
1752:
1750:
1744:
1738:
1731:
1730:public domain
1712:
1710:
1704:
1698:
1696:
1694:
1692:
1690:
1688:
1686:
1670:. 19 May 2016
1669:
1667:
1661:
1655:
1640:
1638:
1629:
1623:
1615:
1611:
1606:
1601:
1597:
1593:
1589:
1585:
1581:
1574:
1566:
1562:
1557:
1552:
1548:
1544:
1540:
1536:
1529:
1522:
1521:public domain
1503:
1501:
1495:
1489:
1487:
1485:
1483:
1481:
1479:
1477:
1475:
1473:
1471:
1469:
1451:
1449:
1444:
1438:
1436:
1434:
1432:
1430:
1428:
1426:
1424:
1407:
1403:
1397:
1395:
1393:
1391:
1389:
1387:
1385:
1383:
1381:
1379:
1377:
1375:
1373:
1371:
1369:
1352:
1348:
1342:
1326:
1325:
1324:Health Canada
1320:
1314:
1298:
1294:
1288:
1272:
1268:
1262:
1246:
1244:
1239:
1233:
1218:. 29 May 2019
1217:
1213:
1207:
1203:
1195:
1192:
1188:
1183:
1181:
1177:
1173:
1169:
1159:
1156:
1154:
1150:
1141:
1138:
1129:
1127:
1121:
1117:
1113:
1111:
1106:
1102:
1098:
1094:
1090:
1089:designation.
1088:
1085:along with a
1084:
1079:
1075:
1072:
1069:
1068:designation.
1067:
1063:
1059:
1055:
1050:
1046:
1044:
1041:
1036:
1034:
1030:
1020:
1018:
1014:
1010:
1006:
1002:
1001:ciprofloxacin
998:
993:
989:
984:
980:
971:
969:
965:
961:
946:
944:
940:
936:
926:
922:
920:
916:
912:
908:
904:
889:
885:
883:
879:
875:
871:
867:
852:
848:
846:
842:
838:
833:
831:
827:
823:
819:
815:
811:
807:
793:
787:
786:
783:
776:
767:
766:
763:
756:
749:
745:
744:
742:
739:
734:
727:
725:
721:
688:
686:
682:
677:
673:
669:
666:
664:
662:ECHA InfoCard
658:
650:
646:
642:
641:
639:
630:
626:
618:
617:RCSB PDB
612:
607:
606:
604:
602:
598:
591:
590:ChEMBL3137309
587:
586:
584:
582:
578:
571:
567:
566:
564:
562:
558:
551:
547:
546:
544:
542:
538:
531:
527:
526:
524:
522:
518:
511:
507:
506:
504:
502:
498:
491:
487:
486:
484:
482:
478:
471:
467:
466:
464:
457:
453:
446:
442:
441:
439:
437:
433:
425:
421:
416:
415:
412:
405:
400:
396:
394:
390:
386:
384:
377:
373:
369:
365:
362:
360:
356:
352:
350:
346:
342:
338:
331:
329: Rx-only
322:
320:
310:
307:
297:
295:
286:
283:
273:
272:
270:
268:
264:
259:
251:
246:
243:
242:
240:
238:
234:
231:
228:
226:
220:
214:
205:
204:
202:
200:
194:
187:
182:
173:
172:
170:
168:
164:
160:
156:
154:
150:
146:
142:
140:
136:
132:
128:
124:
120:
118:
114:
110:
109:
98:
54:
52:Pronunciation
50:
47:Clinical data
45:
41:
36:
32:
27:
19:
5546:Sulfonamides
5531:Orphan drugs
5516:Cyclohexenes
5452:
5408:Pexidartinib
5393:Odronextamab
5363:Gilteritinib
5343:Cabozantinib
5290:
5256:
5231:
5225:Temsirolimus
5207:
5191:
5173:proapoptotic
5171:
5155:
5134:Zanubrutinib
5106:
5076:
5045:
5022:Lestaurtinib
5001:Janus kinase
4999:
4980:
4934:
4927:Non-receptor
4908:Cabozantinib
4901:
4870:Infigratinib
4855:
4829:
4771:Fruquintinib
4753:
4746:Gilteritinib
4742:Lestaurtinib
4735:
4684:
4653:
4626:Mobocertinib
4591:Aumolertinib
4579:
4544:Tremelimumab
4529:Tislelizumab
4484:Retifanlimab
4359:Blinatumomab
4329:Atezolizumab
4300:
4282:
4272:
4254:Obinutuzumab
4232:
4214:
4181:
4164:
4122:
4105:
3965:
3931:Tazemetostat
3895:Alitretinoin
3888:
3799:Estramustine
3779:Elsamitrucin
3769:Eflornithine
3723:Pegaspargase
3719:Asparaginase
3712:
3681:Testolactone
3674:
3662:
3650:
3604:
3589:Panobinostat
3572:
3542:
3530:
3518:
3506:
3477:
3442:
3430:
3383:
3379:Padeliporfin
3318:Dactinomycin
3314:Streptomyces
3295:Temozolomide
3290:Mitozolomide
3278:
3269:Mitobronitol
3258:Procarbazine
3251:
3239:Nonclassical
3164:
3141:
3135:Streptozocin
3100:Nitrosoureas
3098:
3072:Chlorambucil
3066:Trofosfamide
3052:Chlormethine
3047:Bendamustine
3040:
2978:Mitoxantrone
2973:Losoxantrone
2966:
2926:Daunorubicin
2909:
2875:
2812:Camptothecin
2800:
2756:
2726:
2712:
2695:
2679:Fluorouracil
2659:Capecitabine
2652:
2622:
2586:
2572:
2542:
2537:Pralatrexate
2527:Methotrexate
2515:
2458:
2421:
2378:
2262:
2258:
2248:
2236:. Retrieved
2232:
2223:
2211:. Retrieved
2207:FiercePharma
2206:
2197:
2185:. Retrieved
2181:the original
2176:
2167:
2155:. Retrieved
2151:
2142:
2130:. Retrieved
2126:
2117:
2105:. Retrieved
2101:
2098:"venetoclax"
2092:
2080:. Retrieved
2076:the original
2071:
2062:
2050:. Retrieved
2046:
2037:
2025:. Retrieved
2018:the original
2011:
1982:. Retrieved
1978:
1969:
1942:
1938:
1928:
1906:. Retrieved
1897:
1849:. Retrieved
1840:
1798:. Retrieved
1789:
1755:. Retrieved
1746:
1737:
1715:. Retrieved
1706:
1672:. Retrieved
1663:
1654:
1642:. Retrieved
1634:
1622:
1590:(1): 89–98.
1587:
1583:
1573:
1538:
1528:
1506:. Retrieved
1497:
1454:. Retrieved
1446:
1410:. Retrieved
1405:
1355:. Retrieved
1350:
1341:
1329:. Retrieved
1322:
1313:
1301:. Retrieved
1296:
1287:
1275:. Retrieved
1270:
1261:
1249:. Retrieved
1241:
1232:
1220:. Retrieved
1215:
1206:
1184:
1165:
1157:
1142:
1135:
1122:
1118:
1114:
1107:
1103:
1099:
1095:
1091:
1080:
1076:
1073:
1070:
1051:
1047:
1037:
1026:
997:erythromycin
985:
981:
977:
957:
949:Pharmacology
932:
929:Side effects
923:
919:chemotherapy
900:
886:
863:
855:Medical uses
849:
834:
813:
809:
805:
804:
570:CHEBI:133021
445:1257044-40-8
423:
419:
380:Elimination
267:Legal status
261:Legal status
167:License data
18:
5438:Tebentafusp
5418:Regorafenib
5413:Quizartinib
5403:Pemigatinib
5383:Midostaurin
5358:Erdafitinib
5353:Entrectinib
5336:Parsaclisib
5284:Trilaciclib
5274:Palbociclib
5269:Dalpiciclib
5264:Abemaciclib
5166:Aflibercept
5093:Entrectinib
5063:Selumetinib
5058:Cobimetinib
5053:Binimetinib
5037:Ruxolitinib
5027:Momelotinib
5007:Baricitinib
4905:inhibitors:
4882:Pralsetinib
4878:Pemigatinib
4866:Futibatinib
4862:Entrectinib
4859:inhibitors:
4791:Regorafenib
4695:Avapritinib
4641:Rociletinib
4636:Osimertinib
4601:Dacomitinib
4539:Toripalimab
4524:Teclistamab
4514:Talquetamab
4509:Tafasitamab
4504:Sugemalimab
4499:Serplulimab
4489:Sabatolimab
4479:Ramucirumab
4474:Prolgolimab
4444:Necitumumab
4399:Epcoritamab
4379:Dostarlimab
4369:Daratumumab
4324:Amivantamab
4289:Alemtuzumab
4279:Brentuximab
4269:Tositumomab
4244:Ibritumomab
4225:Elranatamab
4188:Bevacizumab
4176:Edrecolomab
4171:Catumaxomab
4133:Trastuzumab
4117:Panitumumab
4006:from market
3976:Vorasidenib
3956:Trabectedin
3941:Tiazofurine
3936:Tebentafusp
3921:Tagraxofusp
3879:Plitidepsin
3849:Mitoguazone
3789:Epacadostat
3759:Demecolcine
3703:Aflibercept
3676:Sex steroid
3549:Fuzuloparib
3490:Carfilzomib
3462:Palbociclib
3452:Abemaciclib
3405:Verteporfin
3369:Efaproxiral
3285:Dacarbazine
3247:Altretamine
3229:Satraplatin
3224:Oxaliplatin
3204:Carboplatin
3181:Triaziquone
3152:Mannosulfan
3130:Ranimustine
3110:Fotemustine
2951:Pirarubicin
2936:Doxorubicin
2930:+cytarabine
2916:Aclarubicin
2877:Podophyllum
2802:Camptotheca
2733:Azacitidine
2719:Gemcitabine
2674:Floxuridine
2607:Fludarabine
2602:Clofarabine
2588:Halogenated
2579:Pentostatin
2554:Raltitrexed
2522:Aminopterin
2465:Ixabepilone
2460:Epothilones
2428:Cabazitaxel
2405:Vinorelbine
2390:Vincristine
2385:Vinblastine
2370:microtubule
2082:21 November
2052:17 November
2027:13 February
1984:16 November
1644:21 November
1137:AbbVie Inc.
1066:orphan drug
1060:along with
1013:fluconazole
1009:dronedarone
935:neutropenia
907:azacitidine
731: g·mol
668:100.254.611
402:Identifiers
153:MedlinePlus
126:Other names
117:Trade names
5506:Benzamides
5490:Categories
5453:Venetoclax
5448:Vandetanib
5423:Ripretinib
5388:Nintedanib
5373:Lenvatinib
5348:Capmatinib
5331:Idelalisib
5321:Copanlisib
5294:inhibitors
5279:Ribociclib
5250:Vismodegib
5235:inhibitors
5215:Everolimus
5181:prohibitin
5098:Lorlatinib
5088:Crizotinib
5068:Trametinib
5032:Pacritinib
5017:Filgotinib
5012:Fedratinib
4916:Crizotinib
4912:Capmatinib
4894:Vandetanib
4842:Brigatinib
4821:Vandetanib
4781:Nintedanib
4776:Lenvatinib
4715:Ripretinib
4646:Vandetanib
4621:Lazertinib
4596:Brigatinib
4519:Tarlatamab
4454:Olaratumab
4414:Isatuximab
4409:Ipilimumab
4389:Elotuzumab
4384:Durvalumab
4364:Cemiplimab
4354:Bermekimab
4344:Axatilimab
4259:Ofatumumab
4239:Glofitamab
4221:Glofitamab
4129:Pertuzumab
3971:Verdinexor
3966:Venetoclax
3869:Oblimersen
3864:Navitoclax
3839:Lucanthone
3834:Lonidamine
3824:Lifileucel
3819:Ivosidenib
3814:Imetelstat
3784:Enasidenib
3774:Elesclomol
3739:Bexarotene
3734:Belzutifan
3669:Bexarotene
3657:Atrasentan
3632:Umbralisib
3627:Idelalisib
3617:Copanlisib
3599:Vorinostat
3594:Romidepsin
3584:Entinostat
3579:Belinostat
3537:Masoprocol
3525:Tiazofurin
3513:Anagrelide
3485:Bortezomib
3472:Seliciclib
3467:Ribociclib
3447:inhibitors
3437:Tipifarnib
3400:Temoporfin
3395:Talaporfin
3333:Plicamycin
3328:Mitomycins
3274:Pipobroman
3253:Hydrazines
3219:Nedaplatin
3171:Carboquone
3166:Aziridines
3157:Treosulfan
3105:Carmustine
3092:Uramustine
3061:Ifosfamide
3033:Alkylating
2994:Bisantrene
2983:Pixantrone
2956:Valrubicin
2946:Idarubicin
2941:Epirubicin
2887:Teniposide
2842:Lurtotecan
2837:Irinotecan
2738:Decitabine
2702:Cytarabine
2645:Pyrimidine
2634:Tioguanine
2624:Thiopurine
2613:Nelarabine
2597:Cladribine
2549:Pemetrexed
2532:Pemetrexed
2508:Folic acid
2448:Paclitaxel
2400:Vinflunine
1539:HemaSphere
1198:References
1153:idelalisib
1097:duration.
915:cytarabine
911:decitabine
880:mutation,
876:deletion,
828:(SLL), or
818:medication
806:Venetoclax
736:3D model (
724:Molar mass
601:PDB ligand
530:N54AIC43PW
501:ChemSpider
436:CAS Number
411:IUPAC name
359:Metabolism
186:Venetoclax
23:Venetoclax
16:Medication
5443:Tepotinib
5433:Sunitinib
5428:Sorafenib
5398:Pazopanib
5378:Masitinib
5326:Duvelisib
5316:Alpelisib
5304:Sotorasib
5299:Adagrasib
5245:Sonidegib
5240:Glasdegib
5186:Adipotide
5119:Ibrutinib
4992:Dasatinib
4987:Bosutinib
4972:Radotinib
4967:Ponatinib
4962:Nilotinib
4952:Dasatinib
4947:Bosutinib
4942:Asciminib
4910:(VEGFR),
4868:(FGFR2),
4847:Ceritinib
4837:Alectinib
4816:Toceranib
4811:Tivozanib
4806:Sunitinib
4801:Sorafenib
4796:Semaxanib
4786:Pazopanib
4766:Cediranib
4730:Toceranib
4725:Sunitinib
4720:Sorafenib
4710:Pazopanib
4705:Masitinib
4672:Tucatinib
4667:Neratinib
4662:Lapatinib
4631:Olmutinib
4611:Gefitinib
4606:Erlotinib
4581:HER1/EGFR
4449:Nivolumab
4439:Naxitamab
4264:Rituximab
4112:Cetuximab
4107:HER1/EGFR
4016:Phase III
4004:Withdrawn
3981:Vosaroxin
3961:Veliparib
3916:Sotorasib
3906:Selinexor
3900:Tretinoin
3890:Retinoids
3804:Glasdegib
3749:Celecoxib
3698:Adagrasib
3622:Duvelisib
3612:Alpelisib
3567:Rucaparib
3554:Niraparib
3495:Oprozomib
3457:Alvocidib
3323:Bleomycin
3280:Triazenes
3264:Etoglucid
3209:Cisplatin
3125:Nimustine
3119:Semustine
3115:Lomustine
3077:Melphalan
3004:Menogaril
2999:Crisnatol
2989:Amsacrine
2961:Zorubicin
2921:Amrubicin
2882:Etoposide
2857:Topotecan
2852:Silatecan
2847:Rubitecan
2832:Gimatecan
2817:Cositecan
2807:Belotecan
2483:inhibitor
2453:Tesetaxel
2443:Ortataxel
2438:Larotaxel
2433:Docetaxel
2395:Vindesine
2265:(1): 73.
1216:Drugs.com
1149:ibrutinib
1017:verapamil
1005:diltiazem
868:(CLL) or
814:Venclyxto
810:Venclexta
393:Excretion
387:~26 hours
382:half-life
353:>99.9%
223:Routes of
197:Pregnancy
145:Monograph
139:Drugs.com
108:-tə-klaks
5480:Medicine
5233:hedgehog
5195:against
5193:exotoxin
5159:against
5108:Bruton's
4957:Imatinib
4880:(FGFR),
4876:(NTRK),
4761:Axitinib
4700:Axitinib
4656:HER2/neu
4616:Icotinib
4586:Afatinib
4560:("-nib")
4339:Avelumab
4211:lymphoid
4203:lymphoma
4199:Leukemia
4124:HER2/neu
4086:("-mab")
3854:Mitotane
3794:Eribulin
3562:Olaparib
3500:Ixazomib
3176:Thiotepa
3148:Busulfan
2827:Exatecan
2664:Carmofur
2372:assembly
2335: /
2291:38201501
2282:10778458
1961:32786187
1908:25 April
1851:25 April
1800:25 April
1757:25 April
1717:25 April
1674:25 April
1614:27806433
1565:27806433
1556:10428728
1508:25 April
1456:25 April
1412:25 April
1406:DailyMed
1357:25 April
1303:31 March
1251:27 April
1222:25 April
1162:Research
1145:US$ 1.48
1043:deletion
837:diarrhea
510:29315017
481:DrugBank
470:49846579
237:ATC code
230:By mouth
199:category
181:DailyMed
4936:bcr-abl
4297:myeloid
2783:S phase
2684:Tegafur
2498:S phase
2423:Taxanes
2359:M phase
2259:Cancers
2238:15 June
2213:15 June
2187:15 June
2177:Reuters
2157:15 June
2132:15 June
2107:15 June
2047:OncLive
1605:5657403
1331:7 April
1277:9 April
1023:History
860:CLL/SLL
832:(AML).
824:(CLL),
816:, is a
685:Formula
490:DB11581
456:PubChem
292::
253:)
247: (
245:L01XX52
212: C
183::
159:a616028
5466:Portal
4183:VEGF-A
3999:WHO-EM
3608:(Pi3K)
2565:Purine
2368:Block
2289:
2279:
2233:AbbVie
1959:
1612:
1602:
1563:
1553:
988:CYP3A4
845:anemia
841:nausea
762:SMILES
729:868.45
581:ChEMBL
550:D10679
372:CYP3A5
368:CYP3A4
319:℞-only
317:
304:
294:℞-only
280:
179:
111:
5177:ANXA2
5149:Other
5047:MAP2K
4918:(ALK)
4903:c-MET
4755:VEGFR
4690:PDGFR
4686:C-kit
4317:Other
4166:EpCAM
3520:IMPDI
3415:Other
2021:(PDF)
2008:(PDF)
1902:(FDA)
1898:U.S.
1845:(FDA)
1841:U.S.
1794:(FDA)
1790:U.S.
1751:(FDA)
1747:U.S.
1711:(FDA)
1707:U.S.
1668:(FDA)
1664:U.S.
1639:(FDA)
1635:U.S.
1631:(PDF)
1502:(FDA)
1498:U.S.
1450:(EMA)
1351:(emc)
1245:(TGA)
1191:Roche
782:InChI
738:JSmol
608:LBM (
561:ChEBI
364:Liver
5292:KRAS
5197:IL-2
5179:and
5161:VEGF
5078:EML4
4737:FLT3
4688:and
4576:ErbB
4302:CD33
4284:CD52
4274:CD30
4234:CD20
4102:ErbB
3606:PIKI
3574:HDAC
3023:CCNS
2287:PMID
2240:2020
2215:2020
2189:2020
2159:2020
2134:2020
2109:2020
2084:2016
2054:2016
2029:2021
1986:2016
1957:PMID
1910:2020
1853:2020
1802:2020
1759:2020
1719:2020
1676:2020
1646:2016
1610:PMID
1561:PMID
1510:2020
1458:2020
1414:2020
1359:2020
1333:2024
1305:2024
1279:2023
1253:2022
1224:2020
1178:and
1151:and
1056:and
878:IGHV
812:and
790:COPY
611:PDBe
541:KEGG
521:UNII
343:data
135:AHFS
5082:ALK
4982:Src
4857:RET
4831:ALK
4281:),
4271:),
4231:),
4216:CD3
4072:L01
3652:ERA
3508:PhI
3479:PrI
3444:CDK
3356:PDT
2354:MIs
2350:SPs
2341:L01
2277:PMC
2267:doi
1947:doi
1943:383
1600:PMC
1592:doi
1588:101
1551:PMC
1543:doi
1040:17p
960:BH3
884:).
882:12+
874:17p
634:EPA
460:CID
306:POM
250:WHO
104:ve-
5492::
4914:,
4884:,
4872:,
4744:,
4683::
4578::
4299::
4227:,
4223:,
4213::
4131:,
4104::
4081:CI
4066:/
4012::
3532:LI
3432:FI
2898:II
2868:II
2690:))
2285:.
2275:.
2263:16
2261:.
2257:.
2231:.
2205:.
2175:.
2150:.
2125:.
2100:.
2070:.
2045:.
2010:.
1994:^
1977:.
1955:.
1941:.
1937:.
1896:.
1871:^
1839:.
1820:^
1788:.
1777:^
1745:.
1705:.
1684:^
1662:.
1633:.
1608:.
1598:.
1586:.
1582:.
1559:.
1549:.
1537:.
1496:.
1467:^
1445:.
1422:^
1404:.
1367:^
1349:.
1321:.
1295:.
1269:.
1240:.
1214:.
1182:.
1174:,
1170:,
1015:,
1011:,
1007:,
1003:,
999:,
909:,
843:,
839:,
702:Cl
699:50
693:45
614:,
370:,
325:EU
313:US
300:UK
289:CA
282:S4
276:AU
208:AU
176:US
106:NE
5468::
5204:)
5200:(
5188:)
5184:(
5168:)
5164:(
5080:-
4994:)
4985:(
4740:(
4732:)
4693:(
4648:)
4584:(
4335:)
4331:(
4309:)
4305:(
4291:)
4287:(
4277:(
4237:(
4219:(
4201:/
4190:)
4186:(
4178:)
4169:(
4150:)
4139:)
4135:(
4127:(
4119:)
4110:(
4074:)
4070:(
4056:e
4049:t
4042:v
3902:)
3893:(
3725:)
3721:/
3717:(
3683:)
3679:(
3671:)
3667:(
3659:)
3655:(
3634:)
3610:(
3601:)
3577:(
3569:)
3547:(
3539:)
3535:(
3527:)
3523:(
3515:)
3511:(
3474:)
3450:(
3439:)
3435:(
3407:)
3388:(
3354:/
3335:)
3316:(
3297:)
3283:(
3260:)
3256:(
3168::
3159:)
3150:(
3145::
3121:)
3117:(
3102::
3083:)
3079:(
3068:)
3059:(
3044::
3025:)
3021:(
2985:)
2971:(
2963:)
2932:)
2928:(
2914:(
2900:+
2889:)
2880:(
2859:)
2805:(
2793:I
2785:)
2781:(
2765:)
2761:(
2740:)
2731:(
2721:)
2717:(
2707:)
2700:(
2686:(
2657:(
2636:)
2627:(
2609:)
2595:(
2590:/
2581:)
2577:(
2556:)
2547:(
2539:)
2520:(
2500:)
2496:(
2467:)
2463:(
2455:)
2426:(
2407:)
2383:(
2361:)
2357:(
2352:/
2343:)
2339:(
2324:e
2317:t
2310:v
2293:.
2269::
2242:.
2217:.
2191:.
2161:.
2136:.
2111:.
2086:.
2056:.
2031:.
1988:.
1963:.
1949::
1923:.
1912:.
1866:.
1855:.
1815:.
1804:.
1772:.
1761:.
1732:.
1721:.
1678:.
1648:.
1616:.
1594::
1567:.
1545::
1523:.
1512:.
1460:.
1416:.
1361:.
1335:.
1307:.
1281:.
1255:.
1226:.
992:5
990:/
740:)
717:S
714:7
711:O
708:7
705:N
696:H
690:C
636:)
632:(
620:)
424:H
420:N
374:)
366:(
327::
315::
302::
278::
210::
137:/
97:/
94:s
91:k
88:æ
85:l
82:k
79:ə
76:t
73:ɛ
70:n
67:ˈ
64:ɛ
61:v
58:/
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
